Postherpetic Neuralgia Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

(Albany, USA) DelveInsight's "Postherpetic Neuralgia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Postherpetic Neuralgia Market with DelveInsight's In-Depth Report @ Postherpetic Neuralgia Treatment Market Size- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Postherpetic Neuralgia Market Report
• In June 2025, Ono Pharmaceutical Co. Ltd announced a Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Postherpetic Neuralgia.
• The total Postherpetic Neuralgia incident cases in the 7MM were approximately 600,000 in 2023. These cases are expected to increase by 2034.
• Among the 7MM, the United States accounted for the highest number of incident cases of PHN, i.e., ~300,000 cases in 2023.
• According to estimates, Postherpetic Neuralgia is slightly more common in females than males, accounting for ~60% of the total cases, while males accounted for ~40% of the total population share.
• Among EU4 and the UK, Germany accounted for the largest number of Postherpetic Neuralgia cases, followed by France, whereas Spain accounted for the lowest number of cases in 2023.
• The leading Postherpetic Neuralgia Companies such as Merz Therapeutics GmbH, Lexicon Pharmaceuticals, Merz Therapeutics, Scilex Pharmaceuticals, Daiichi Sankyo, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Promising Postherpetic Neuralgia Pipeline Therapies such as IncobotulinumtoxinA, LX9211, XEOMIN (IncobotulinumtoxinA), ZTlido (lidocaine), TARLIGE (mirogabalin besilate), HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, GEn, and others.

Stay ahead in the Postherpetic Neuralgia Therapeutics Market with DelveInsight's Strategic Report @ Postherpetic Neuralgia Market Outlook- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Epidemiology Segmentation in the 7MM
• Total Postherpetic Neuralgia Incident Cases
• Postherpetic Neuralgia Gender-Specific Cases
• Postherpetic Neuralgia Age-Specific Cases
• Total Postherpetic Neuralgia Treated Cases

Download the report to understand which factors are driving Postherpetic Neuralgia epidemiology trends @ Postherpetic Neuralgia Prevalence- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Marketed Drugs
• ZTLIDO (topical lidocaine system): Scilex Pharmaceuticals
ZTLIDO is a topical lidocaine system (1.8%) approved for relieving pain associated with postherpetic neuralgia. ZTLIDO is designed as a lighter, thinner product with improved adhesion relative to lidoderm (lidocaine patch 5%) while providing a bioequivalent delivery of lidocaine in an efficient drug delivery system. Lidocaine is a local amide anesthetic; it blocks sodium ion channels required for initiating and conducting neuronal impulses. The drug received FDA approval in February 2018 for relieving pain associated with postherpetic neuralgia.

• TARLIGE (mirogabalin besilate): Daiichi Sankyo
TARLIGE is an analgesic proprietarily discovered by Daiichi Sankyo that works by inhibiting the excessive release of pain-related neurotransmitters in the presynaptic nerve terminal. Mirogabalin exerts an analgesic effect by suppressing calcium current through binding to the a2d subunit, which plays an auxiliary role in the function of voltage-gated calcium channels in the nervous system. Generally, for adults, the initial dose of mirogabalin is 5 mg orally twice daily, and then the dose is gradually increased by 5 mg at intervals of 1 week or longer to 15 mg orally twice daily. The drug was approved for marketing in Japan in January 2019 based on the results of Phase III clinical trials conducted in Asia, including Japan, in patients with diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia for peripheral neuropathic pain (PNP).

Postherpetic Neuralgia Emerging Drugs
• LX9211: Lexicon Pharmaceuticals
LX9211 is a potent, orally delivered, selective small molecule inhibitor of adaptor-associated kinase 1 (AAK1). It was discovered using Lexicon's unique approach to gene science. Preclinical studies of LX9211 demonstrated that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain. LX9211 was identified in a neuroscience drug discovery alliance with Bristol-Myers Squibb, from which Lexicon holds exclusive development and commercialization rights. The company has completed a Phase II clinical trial (NCT04662281; RELIEF-PHN1) of LX9211 in adults associated with postherpetic neuralgia and has shown clear evidence of an effect. Topline results were announced in December 2022.

• IncobotulinumtoxinA (NT 201): Merz Therapeutics
IncobotulinumtoxinA, marketed as XEOMIN, is approved in over 75 countries worldwide to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm, glabellar lines, and sialorrhea. The drug effectively treats peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles. It also relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. It is free from complex proteins and has a low risk of neutralizing antibody formation.

Get In-Depth Knowledge on Postherpetic Neuralgia Market Trends and Forecasts with DelveInsight @ Postherpetic Neuralgia Treatment Market- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postherpetic Neuralgia Drugs Market Insights
FDA-approved treatments for postherpetic neuralgia (PHN) include analgesics, anticonvulsants, and topical solutions. Antiiconvulsants such as Gabapentin, Pregabalin are commonly used to treat neuropathic pain that work by stabilizing electrical activity in the nerves and reducing abnormal signalling. Tricyclic Antidepressants like Amitriptyline, Nortriptyline modulate pain signals in the central nervous system. Opioids (e.g., oxycodone, morphine), strong pain relievers may be prescribed for severe postherpetic neuralgia pain.

Postherpetic Neuralgia Market Outlook
Postherpetic neuralgia is associated with significant loss of function and reduced quality of life, particularly in the elderly, and is highly resistant to treatment. Since postherpetic neuralgia is often resistant to pharmacologic treatments, a multimodal analgesic treatment strategy is often used to balance the efficacy and tolerability of the medication regimen, the side effects of which can be limiting and compromise the quality of life and patient compliance. Postherpetic neuralgia has no cure, and patients rely on palliative treatments to reduce pain duration and severity.

Unlock Strategic Insights with DelveInsight's Comprehensive Postherpetic Neuralgia Market Report @ Postherpetic Neuralgia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Postherpetic Neuralgia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Postherpetic Neuralgia Companies- Merz Therapeutics GmbH, Lexicon Pharmaceuticals, Merz Therapeutics, Scilex Pharmaceuticals, Daiichi Sankyo, Haisco Pharma, Xenon Pharma, Winston Laboratories, Teva Branded Pharma, Aestus Therapeutics, KAI Pharma, Takeda, Daewoong Pharma, Zalicus, Bausch Health Americas, Inc., UCB Pharma, XenoPort, Inc., and others
• Postherpetic Neuralgia Pipeline Therapies- IncobotulinumtoxinA, LX9211, XEOMIN (IncobotulinumtoxinA), ZTlido (lidocaine), TARLIGE (mirogabalin besilate), HSK16149, XPF-002, Civamide Patch, TV-45070, ATx08-001, KAI-1678, TAK-583, DWP05195, Z160, Retigabine, Levetiracetam, GEn, and others.
• Postherpetic Neuralgia Therapeutic Assessment: Postherpetic Neuralgia current marketed and Postherpetic Neuralgia emerging therapies
• Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia market drivers and Postherpetic Neuralgia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Postherpetic Neuralgia Unmet Needs, KOL's views, Analyst's views, Postherpetic Neuralgia Market Access and Reimbursement

Get a Free sample for the Postherpetic Neuralgia Market Report @ https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Postherpetic Neuralgia Market Report Introduction
2. Executive Summary for Postherpetic Neuralgia
3. SWOT analysis of Postherpetic Neuralgia
4. Postherpetic Neuralgia Patient Share (%) Overview at a Glance
5. Postherpetic Neuralgia Market Overview at a Glance
6. Postherpetic Neuralgia Disease Background and Overview
7. Postherpetic Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Postherpetic Neuralgia
9. Postherpetic Neuralgia Current Treatment and Medical Practices
10. Postherpetic Neuralgia Unmet Needs
11. Postherpetic Neuralgia Emerging Therapies
12. Postherpetic Neuralgia Market Outlook
13. Country-Wise Postherpetic Neuralgia Market Analysis (2020-2034)
14. Postherpetic Neuralgia Market Access and Reimbursement of Therapies
15. Postherpetic Neuralgia Market Drivers
16. Postherpetic Neuralgia Market Barriers
17. Postherpetic Neuralgia Appendix
18. Postherpetic Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.